MedTrace Logo

Treatment of Asymptomatic Toxocariasis With Albendazole in Children

NCT00755560 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-03-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate effectiveness of albendazole in the treatment of the asymptomatic infection with the parasite Toxocara in children. Treatment response is defined as a reduction in the number of eosinophils in blood. The study drug will be compared to placebo and randomly assigned in a double blind manner. Follow up will be prospective. 50 children (25 per group) will be enrolled in the study.

Conditions

  • Toxocariasis

Interventions

DRUG

Albendazole

Albendazole 10 - 15 mg/kg/day BID for 15 days

DRUG

Placebo

Placebo BID for 15 days

Sponsors & Collaborators

  • Hospital de Niños R. Gutierrez de Buenos Aires

    lead OTHER

Principal Investigators

  • Jaime Altcheh, MD · Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires

  • Hector Freilij, MD · Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2015-07-31
Completion
2025-07-31

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00755560 on ClinicalTrials.gov